#eversense

Senseonics Holdings, Inc. (NYSE American: SENS) and Rimidi are teaming up to create the Eversense Remote Patient Monitoring (RPM) Program, which will focus on improving diabetes care using new technology. Rimidi, known for its clinical management platform, wants to make managing chronic diseases, especially diabetes, easier for patients.

The partnership will combine Eversense glucose data with Rimidi's clinical management platform, which is used by health systems, health plans, and doctor's offices. This will work with Medicare's remote patient monitoring telehealth programs and fit into existing Electronic Health Record (EHR) systems. The goal is to improve care quality, streamline workflows, engage patients, and help with clinical decisions.

The Eversense CGM + RPM solution, with Rimidi's help, will securely send patient glucose data to popular EHR systems. This will give healthcare providers a better view of glucose trends, frequency of high or low events, and time spent in the target range. With this information, providers can work with patients to improve their lifestyle and therapy choices, leading to better diabetes management, lower costs, and better outcomes.

Tim Goodnow, PhD, President and CEO of Senseonics, explained that the Eversense RPM Program is part of their plan to combine long-term CGM technology with advanced analytics and personalized health services for a complete diabetes solution. This program aims to give providers the data they need to improve care between visits, where most diabetes management happens. The Eversense CGM+RPM solution, along with Rimidi's platform, aims to set Eversense apart from other CGM makers by offering a complete solution.

Senseonics Launches Eversense CGM System with New App in the U.S.

Senseonics, a company developing an implantable continuous glucose monitoring (CGM) system announced that Eversense users who use the new app can start dosing insulin based on readings from their system without first doing a fingerstick.

“We’re very pleased that today, the new Eversense app is available from the Apple App and Google Play stores, so now users in the United States can take full…

Senseonics Announces Expanded Coverage for Eversense CGM

Senseonics Holdings, Inc., a company developing the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Health Care Service Corporation (HCSC) – Blue Cross Blue Shield is now providing coverage for the Eversense CGM System.

The expanded coverage became effective on October 15, 2019.

This decision adds to the growing number of…

Al via #diabeteontheroad – la piena libertà di essere sé stessi .

Roche Diabetes Care Italy racconta le esperienze delle persone che utilizzano il sensore impiantabile per il monitoraggio in continuo della glicemia.

Un viaggio in alcuni importanti Centri diabetologici italiani alla scoperta delle persone che, grazie al sensore impiantabile, vivono una nuova vita con il diabete, dei loro medici fautori della libertà ritrovata e delle città in cui vivono.

Un…

Senseonics Announces New Insurance Coverages for Eversense CGM

Senseonics Holdings, maker of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced new coverages by Blue Cross Blue Shield.

Blue Cross Blue Shield of Massachusetts and Blue Cross Blue Shield of Idaho will now provide coverage for Eversense CGM.

These recent coverage decisions add to the growing number of payers who are writing…